Daniel et al, the main reason I don’t buy into what you are saying is we would have gotten a PR from NWBO regarding a BLA. Big pharma may not PR when they submit their BLA because it won’t affect their share price much but a PR saying such would give a big boost to NWBO. Secondly, I would think NWBO would apply for Breakthrough Therapy Designation and soon after getting the designation, PR it, and we haven’t heard a peep about that. And if the review was being considered under Project Orbis, we would still hear about DCVax-L getting BTD. The first Project Orbis drug approved was Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment, it got a BTD PR on July 23, 2019 and approved in Sept 2019. So I don’t buy this stealth stuff. We’ll know TLD and have Journal article and/or conference abstract first and THEN we’ll start hearing about the BLA process. IMHO
Market Data 
Markets 
AI
